| Literature DB >> 33008442 |
Cheng Li1, Christina Ojeda Thies2, Chi Xu3, Andrej Trampuz4.
Abstract
BACKGROUND: Because there is no single gold standard method for the diagnosis of periprosthetic joint infection (PJI), the combination of valuable methods to evaluate infection appears to achieve a better diagnostic result. The objective of the present study was to evaluate the diagnostic value of serum interleukin (IL)-6 and C-reactive protein (CRP) for the diagnosis of PJI.Entities:
Keywords: Arthroplasty; C-reactive protein; Diagnosis; Interleukin-6; Meta-analysis; Periprosthetic joint infection; Serum
Mesh:
Substances:
Year: 2020 PMID: 33008442 PMCID: PMC7532114 DOI: 10.1186/s13018-020-01864-7
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Fig. 1Flow diagram of the selection process for eligible studies
Characteristics of the included studies for meta-analysis
| Reference | Year | Country | Study design | Enrollment period | Patients | Location | Sample | Cut-off | Sen | Spe | Standard | Received antibiotics | Excluded inflammatory disease |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [ | 2010 | Argentina | Prospective study | February 2007 and July 2008 | 69 | Hip | IL-6 | 10 pg/ml | 36% | 94% | H, M | N | Y |
| CRP | 10 mg/l | 72% | 91% | ||||||||||
IL-6 + CRP (Serial tests) | 57% | 100% | |||||||||||
| [ | 2007 | Germany | Prospective study | July 2003 and March 2004 | 78 | Hip, knee | IL-6 | > 12 pg/ml | 95% | 87% | H, M | NA | N |
| CRP | > 3.2 mg/l | 95% | 96% | ||||||||||
IL-6 + CRP (Parallel test) | 100% | 86% | |||||||||||
| [ | 2017 | Turkey | Prospective study | April 2010 and December 2012 | 85 | Knee | IL-6 | 6.6 pg/ml | 95% | 96% | MSIS | N | Y |
| CRP | 8.83 mg/l | 95% | 90% | ||||||||||
IL-6 + CRP (Parallel test) | 99% | 98% | |||||||||||
| [ | 2013 | Egypt | Prospective study | NA | 40 | Hip, knee | IL-6 | > 10.4 pg/ml | 100% | 90.90% | H, M, P | N | Y |
| CRP | > 18 mg/l | 100% | 86.20% | ||||||||||
IL-6 + CRP (Serial tests) | 100% | 99% | |||||||||||
| [ | 2019 | USA | Prospective study | January 2017 to December 2019 | 52 | Knee | IL-6 | > 9.14 pg/ml | 81.30% | 63% | MSIS | NA | Y |
| CRP | > 17 mg/l | 66.70% | 66.70% | ||||||||||
IL-6 + CRP (Serial tests) | 33.30% | 85.0% | |||||||||||
IL-6 + CRP (Parallel test) | 93.8% | 45.8% | |||||||||||
| [ | 2013 | Austria | Prospective study | March 2008 and June 2010 | 84 | Hip, knee | IL-6 | 4.7 pg/ml | 81% | 68% | MSIS | Y | Y |
| CRP | 17.05 mg/l | 84% | 79% | ||||||||||
IL-6 + CRP (Parallel test) | 84% | 68% | |||||||||||
| [ | 2015 | Germany | Prospective study | NA | 77 | Hip, knee | IL-6 | > 5.12 pg/ml | 80% | 87.70% | MSIS | N | Y |
| CRP | ≥ 3 mg/l | 80% | 64% | ||||||||||
IL-6 + CRP (Serial tests) | 75% | 98.20% | |||||||||||
| [ | 2017 | China | Prospective study | August 2013 and August 2016 | 160 | Hip, knee | IL-6 | 6.9 pg/ml | 96.60% | 78% | MSIS | NA | Y |
| CRP | 8.54 mg/l | 79.70% | 83.80% | ||||||||||
IL-6 + CRP (Serial tests) | 76.30% | 93.10% | |||||||||||
IL-6 + CRP (Parallel test) | 100% | 69.3% |
C clinical signs of infection, CRP C-reactive protein, H histological examination, IL-6 interleukin-6, M microbiological or laboratory examination, MSIS Musculoskeletal Infection Society, NA not available, N no, P presence of sinus tract or purulence around the prosthesis, SEN sensitivity, SPE specificity, Y yes
Bacterial species detected in the included studies
| Reference | Infected cases | Pathogenic bacteria (numbers) |
|---|---|---|
| 1 | 11 | Coagulase-negative |
| Methicillin-resistant | ||
| 2 | 21 | |
| Polymicrobial infection (5) | ||
| 3 | 45 | |
| Coagulase-negative | ||
| 4 | 11 | |
| Coagulase-negative | ||
| 5 | 32 | Methicillin-sensitive |
| Coagulase-negative | ||
| Methicillin-resistant | ||
| Others (1) | ||
| 6 | 55 | |
| Culture-negative infection (16) | ||
| Polymicrobial infection (1) | ||
| 7 | 20 | |
| Culture-negative infection (3) | ||
| Polymicrobial infection (1) | ||
Fig. 2Methodological quality assessment of the included studies
Fig. 3Forest plots of sensitivity for the combined method (A), IL-6 (B), and CRP (C)
Fig. 4Forest plots of specificity for the combined method (A), IL-6 (B), and CRP (C)
Fig. 5Forest plots of the positive likelihood ratio for the combined method (A), IL-6 (B), and CRP (C)
Fig. 6Forest plots of the negative likelihood ratio for the combined method (A), IL-6 (B), and CRP (C)
Fig. 7Forest plots of the diagnostic odds ratio for the combined method (A), IL-6 (B), and CRP (C)
Fig. 8Summary of SROC for the combined method (A), IL-6 (B), and CRP (C)
Subgroup analysis of parallel and series tests for PJI diagnosis
| Diagnostic method | Number of studies | Sen (95% CI) | Spe (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUC |
|---|---|---|---|---|---|---|---|
| 10 | 0.84 (0.80−0.88) | 0.85 (0.82–0.88) | 5.98 (3.24−11.01) | 0.17 (0.07−0.39) | 58.35 (18.04−188.79) | 0.9453 | |
| IL-6 | 8 | 0.87 (0.82−0.90) | 0.83 (0.79−0.87) | 4.95 (3.19−7.68) | 0.16 (0.07−0.38) | 36.27 (12.67−103.88) | 0.9237 |
| CRP | 8 | 0.84 (0.79−0.88) | 0.83 (0.79−0.87) | 4.97 (3.03−8.17) | 0.21 (0.12−0.36) | 27.24 (10.61−69.91) | 0.9074 |
| 5 | 0.94 (0.90−0.97) | 0.74 (0.69−0.79) | 3.67 (2.06−6.53) | 0.05 (0.01−0.31) | 79.52 (11.18−565.82) | 0.9563 | |
| IL-6 | 5 | 0.89 (0.84−0.93) | 0.79 (0.74−0.84) | 4.28 (2.46−7.45) | 0.12 (0.04−0.33) | 43.55 (9.41−201.58) | 0.9327 |
| CRP | 5 | 0.84 (0.78−0.88) | 0.85 (0.80−0.89) | 5.32 (2.76−10.25) | 0.19 (0.09−0.39) | 32.67 (8.91−119.81) | 0.9180 |
| 5 | 0.66 (0.57−0.74) | 0.96 (0.92−0.98) | 14.26 (4.05−50.24) | 0.34 (0.15−0.76) | 53.94 (8.45−344.35) | 0.9421 | |
| IL-6 | 5 | 0.86 (0.79−0.91) | 0.83 (0.78−0.88) | 4.55 (2.82−7.35) | 0.19 (0.06−0.66) | 26.49 (8.30−84.55) | 0.9056 |
| CRP | 5 | 0.77 (0.69−0.84) | 0.80 (0.75−0.85) | 3.85 (2.25−6.57) | 0.31 (0.20−0.50) | 13.28 (5.19−34) | 0.8537 |
AUC area under the curve, CI confidence interval, CRP C-reactive protein, DOR diagnostic odds ratio, IL-6 interleukin-6, PLR positive likelihood ratio, NLR negative likelihood ratio, SEN sensitivity, SPE specificity